Abstract
Cardiomyopathies are a heterogeneous group of primary diseases of the myocardium usually of genetic origin and with familial presentation. The identification of multiple genetic causes for these diseases has opened a new window for early diagnosis, understanding of their natural history and improvement in risk stratification and management. However, in the past years, the clinical application of genetics has been limited by the prohibiting cost and restricted yield of the available genotyping technologies. The emergence of Next Generation Sequencing (NGS) has completely changed this scenario. This group of sequencing technologies allow the evaluation of hundreds or even thousands of genes in parallel at an affordable cost. Now the challenge is not genotyping per se but the interpretation of the complex results that NGS generates. In this paper we review the main aspects related to the application and impact of Next Generation Sequencing in the study of cardiomyopathies: technology, analysis procedures, bioinformatics, clinical validation and interpretation of results.
Keywords: Cardiomyopathies, genetics, next generation sequencing.
Current Pharmaceutical Design
Title:Genetics of Cardiomyopathies: Novel Perspectives with Next Generation Sequencing
Volume: 21 Issue: 4
Author(s): Lorenzo Monserrat, Martin Ortiz-Genga, Ivan Lesende, Diego Garcia-Giustiniani, Roberto Barriales-Villa, David de Una-Iglesias, Petros Syrris and Alfonso Castro-Beiras
Affiliation:
Keywords: Cardiomyopathies, genetics, next generation sequencing.
Abstract: Cardiomyopathies are a heterogeneous group of primary diseases of the myocardium usually of genetic origin and with familial presentation. The identification of multiple genetic causes for these diseases has opened a new window for early diagnosis, understanding of their natural history and improvement in risk stratification and management. However, in the past years, the clinical application of genetics has been limited by the prohibiting cost and restricted yield of the available genotyping technologies. The emergence of Next Generation Sequencing (NGS) has completely changed this scenario. This group of sequencing technologies allow the evaluation of hundreds or even thousands of genes in parallel at an affordable cost. Now the challenge is not genotyping per se but the interpretation of the complex results that NGS generates. In this paper we review the main aspects related to the application and impact of Next Generation Sequencing in the study of cardiomyopathies: technology, analysis procedures, bioinformatics, clinical validation and interpretation of results.
Export Options
About this article
Cite this article as:
Monserrat Lorenzo, Ortiz-Genga Martin, Lesende Ivan, Garcia-Giustiniani Diego, Barriales-Villa Roberto, Una-Iglesias de David, Syrris Petros and Castro-Beiras Alfonso, Genetics of Cardiomyopathies: Novel Perspectives with Next Generation Sequencing, Current Pharmaceutical Design 2015; 21 (4) . https://dx.doi.org/10.2174/138161282104141204123748
DOI https://dx.doi.org/10.2174/138161282104141204123748 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect of Licorice Drink on the Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets The Cardiac Antihypertrophic Effects of Cyclic GMP-Generating Agents: An Experimental Framework for Novel Treatments of Left Ventricular Remodeling
Vascular Disease Prevention (Discontinued) Editorial: (Thematic Issue: Novel Strategies for Cardiac Repair Post-Myocardial Infarction)
Current Pharmaceutical Design CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Targeting Mitochondria for Cardiac Protection
Current Drug Targets Surrogates of Insulin Sensitivity and Indices of Cardiometabolic Profile in Obesity
Current Vascular Pharmacology Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry The Role of the Chemokines in Myocardial Ischemia and Reperfusion
Current Vascular Pharmacology Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Adult Stem Cells and Biocompatible Scaffolds as Smart Drug Delivery Tools for Cardiac Tissue Repair
Current Medicinal Chemistry Oxytocin and Diabetes Mellitus: A Strong Biochemical Relation. Review
Current Diabetes Reviews Cardiovascular Risk Factors, Metabolic Complications, & the Natural Course of CKD in Children
Current Hypertension Reviews Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design